Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Marija Zaric

Postdoctoral Immunologist

Marija joined Biswas’ group as a Postdoctoral Immunologist in 2017. She oversees and investigates the immunology on Phase I trials of transmission-blocking malaria vaccines, both in the UK and in field trials in Africa, assessing the magnitude of the immune responses generated after trail vaccinations. Her main interest is in exploring the cellular mechanisms that influence humoral immunity in the context of transmission-blocking malaria vaccines and generation of monoclonal antibodies against sexual- and mosquito-stages of the malaria parasite. 

Prior to joining the Jenner Institute, Marija worked as a Postdoctoral Research fellow on a Marie Curie funded project in Klavinskis’ lab, at the King’s College London, that explored cellular and molecular mechanisms by which anti-viral vaccines and immune adjuvants induced adaptive immunity and how antigen modification influenced the breadth of vaccine-specific CD8+ T cell responses. 

Marija obtained her BMBS Degree from the School of Medicine, University of Belgrade in Serbia, before completing her PhD with Adrien Kissenpfennig at the Queen’s University Belfast, where she investigated microneedle-mediated delivery of tumour and viral antigens as a mean of targeting skin dendritic cells in vivo and promoting enhanced anti-cancer and anti-viral immunity. 

Publications

A Universal Plug-and-Display Vaccine Carrier Based on HBsAg VLP to Maximize Effective Antibody Response.

Marini A, Zhou Y, Li Y, Taylor IJ, Leneghan DB, Jin J, Zaric M, Mekhaiel D, Long CA, Miura K, Biswas S. Front Immunol. 2019 Dec 12;10:2931. doi: 10.3389/fimmu.2019.02931. eCollection 2019.

 

Skin immunisation activates an innate lymphoid cell-monocyte axis regulating CD8+ effector recruitment to mucosal tissues.

Zaric M, Becker PD, Hervouet C, Kalcheva P, Doszpoly A, Blattman N, A O' Neill L, Yus BI, Cocita C, Kwon SY, Baker AH, Lord GM, Klavinskis LS. Nat Commun. 2019 May 17;10(1):2214. doi: 10.1038/s41467-019-09969-2.

 

Long-lived tissue resident HIV-1 specific memory CD8+ T cells are generated by skin immunization with live virus vectored microneedle arrays.

Zaric M, Becker PD, Hervouet C, Kalcheva P, Ibarzo Yus B, Cocita C, O'Neill LA, Kwon SY, Klavinskis LS. J Control Release. 2017 Dec 28;268:166-175. doi: 10.1016/j.jconrel.2017.10.026. Epub 2017 Oct 19.

 Microneedle-mediated delivery of viral vectored vaccines.

Zaric M, Ibarzo Yus B, Kalcheva PP, Klavinskis LS.

Expert Opin Drug Deliv. 2017 Oct;14(10):1177-1187. doi: 10.1080/17425247.2017.1230096. Epub 2016 Sep 7. Review.

 Dissolving microneedle delivery of nanoparticle-encapsulated antigen elicits efficient cross-priming and Th1 immune responses by murine Langerhans cells.

Zaric M, Lyubomska O, Poux C, Hanna ML, McCrudden MT, Malissen B, Ingram RJ, Power UF, Scott CJ, Donnelly RF, Kissenpfennig A.

J Invest Dermatol. 2015 Feb;135(2):425-434. doi: 10.1038/jid.2014.415. Epub 2014 Sep 22.

 

Laser-engineered dissolving microneedle arrays for protein delivery: potential for enhanced intradermal vaccination.

McCrudden MT, Torrisi BM, Al-Zahrani S, McCrudden CM, Zaric M, Scott CJ, Kissenpfennig A, McCarthy HO, Donnelly RF.J Pharm Pharmacol. 2015 Mar;67(3):409-25. doi: 10.1111/jphp.12248. Epub 2014 Mar 27.

 

Skin dendritic cell targeting via microneedle arrays laden with antigen-encapsulated poly-D,L-lactide-co-glycolide nanoparticles induces efficient antitumor and antiviral immune responses.

Zaric M, Lyubomska O, Touzelet O, Poux C, Al-Zahrani S, Fay F, Wallace L, Terhorst D, Malissen B, Henri S, Power UF, Scott CJ, Donnelly RF, Kissenpfennig A. ACS Nano. 2013 Mar 26;7(3):2042-55. doi: 10.1021/nn304235j. Epub 2013 Feb 15.

 

Microneedle-mediated vaccine delivery: harnessing cutaneous immunobiology to improve efficacy.

Al-Zahrani S*, Zaric M*, McCrudden C, Scott C, Kissenpfennig A, Donnelly RF.

Expert Opin Drug Deliv. 2012 May;9(5):541-50. doi: 10.1517/17425247.2012.676038. Epub 2012 Apr 5. Review.

 

Altered Toll-like receptor 2-mediated endotoxin tolerance is related to diminished interferon beta production.

Zaric SS, Coulter WA, Shelburne CE, Fulton CR, Zaric M, Scott A, Lappin MJ, Fitzgerald DC, Irwin CR, Taggart CC.J Biol Chem. 2011 Aug 26;286(34):29492-500. doi: 10.1074/jbc.M111.252791. Epub 2011 Jun 24.